Melissa Vitale
Psychiatric/Mental Health · Chicago, ILNPI 1952867681
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $100,050 of the $150,577 with a category attached, or 66.4%. Johnson & Johnson accounts for 96.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $45,685 and has fallen 52.6% since, to $21,634 in 2025. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $311.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$145K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$606
- Otsuka America Pharmaceutical, Inc.$589
- Takeda Pharmaceuticals U.S.A., Inc.$389
- plus $2K from 14 others
What the payments were for
- Consulting fees$19,89013%
- Speaking & faculty fees$100,05066%
- Travel & lodging$21,33514%
- Food & beverage$9,2086%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 240 | $144,969 |
| AbbVie | 52 | $1,145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $1,060 |
| Lundbeck LLC | 35 | $606 |
| Otsuka America Pharmaceutical, Inc. | 31 | $589 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $389 |
| Teva Pharmaceuticals USA, Inc. | 9 | $310 |
| Neurocrine Biosciences, Inc. | 14 | $310 |
| Vanda Pharmaceuticals Inc. | 11 | $309 |
| Alkermes, Inc. | 9 | $254 |
| Axsome Therapeutics, Inc. | 9 | $246 |
| Bausch Health US, LLC | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Neos Therapeutics, LP | 3 | $46 |
| Corium, LLC | 1 | $26 |
| Bioxcel Therapeutics, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$140,776
- INVEGA TRINZA$139,893
- INVEGA$1,020
- CAPLYTA$327
- VRAYLAR$240
- UZEDY$125
- Auvelity$110
How this compares
$150,577 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Chicago
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Alan AmbergChicago$119K
- Julie CarbrayChicago$36K
- Abigail HamiltonChicago$14K
- Anh NguyenChicago$9K
- Sherann IvyChicago$8K
- Annabella Vidal-RuizChicago$8K
- Dina Pierre-GrayChicago$7K
- Natalia RysmanowskaChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.